High materiality7/10
Piper Sandler on Kymera Therapeutics (KYMR): 'All Eyes on BroADen2 Data in 4Q'
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Piper Sandler targets KYMR at $140; current price $119.90; price change -4.53 since signal.
- Piper Sandler target $140 on KYMR; price $119.90 (-4.53) since signal.
Key facts
- 01
Target: $140
- 02
Posted price: $119.9
- 03
Analyst firm: Piper Sandler
- 04
Analyst: Biren Amin
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.